Multi-ethnic study of atherosclerosis: Objectives and design
Multi-ethnic study of atherosclerosis: Objectives and design
复制标题
DOI：
10.1093/aje/kwf113
复制
发表时间：
2002-11-01
影响因子：
5
通讯作者：
Tracy, RP
中科院分区：
文献类型：
--
作者：
Bild, DE;Bluemke, DA;Tracy, RP
动脉粥样硬化多种族研究于2000年7月启动，目的是调查亚临床心血管疾病（CVD）的患病率、相关性和进展，研究对象为6500名年龄在45-84岁之间的男性和女性。该队列将从美国六个实地研究中心中选出。大约38%的队列将是白人，28%的非裔美国人，23%的西班牙裔，11%的亚洲人（中国血统）。基线测量将包括使用计算机断层扫描测量冠状动脉钙；应用心脏磁共振成像技术测量心室质量和功能超声测量血流介导的肱动脉内皮血管舒张、颈动脉内内壁厚度和颈动脉扩张性；踝、肱血压测量外周血管病变心电描记法;微量白蛋白尿、标准心血管疾病危险因素、社会人口因素、生活习惯和社会心理因素的评估。血液样本将分析推定的生化危险因素，并储存起来用于巢式病例对照研究。DNA将被提取，淋巴细胞将被永生用于基因研究。选定的亚临床疾病指标和危险因素的测量将在7年的进展研究中重复进行。参与者将被跟踪到2008年，以识别和描述CVD事件，包括急性心肌梗死和其他冠心病、中风、周围血管疾病和充血性心力衰竭；心血管疾病的治疗干预；和死亡率。
The Multi-Ethnic Study of Atherosclerosis was initiated in July 2000 to investigate the prevalence, correlates, and progression of subclinical cardiovascular disease (CVD) in a population-based sample of 6,500 men and women aged 45-84 years. The cohort will be selected from six US field centers. Approximately 38% of the cohort will be White, 28% African-American, 23% Hispanic, and 11% Asian (of Chinese descent). Baseline measurements will include measurement of coronary calcium using computed tomography; measurement of ventricular mass and function using cardiac magnetic resonance imaging; measurement of flow-mediated brachial artery endothelial vasodilation, carotid intimal-medial wall thickness, and distensibility of the carotid arteries using ultrasonography; measurement of peripheral vascular disease using ankle and brachial blood pressures; electrocardiography; and assessments of microalbuminuria, standard CVD risk factors, sociodemographic factors, life habits, and psychosocial factors. Blood samples will be assayed for putative biochemical risk factors and stored for use in nested case-control studies. DNA will be extracted and lymphocytes will be immortalized for genetic studies. Measurement of selected subclinical disease indicators and risk factors will be repeated for the study of progression over 7 years. Participants will be followed through 2008 for identification and characterization of CVD events, including acute myocardial infarction and other coronary heart disease, stroke, peripheral vascular disease, and congestive heart failure; therapeutic interventions for CVD; and mortality.